UK markets close in 2 hours 34 minutes
  • FTSE 100

    7,518.31
    -40.18 (-0.53%)
     
  • FTSE 250

    19,331.29
    -78.13 (-0.40%)
     
  • AIM

    854.63
    +4.07 (+0.48%)
     
  • GBP/EUR

    1.1647
    +0.0004 (+0.04%)
     
  • GBP/USD

    1.2182
    -0.0074 (-0.60%)
     
  • BTC-GBP

    13,888.73
    -183.53 (-1.30%)
     
  • CMC Crypto 200

    401.20
    -4.95 (-1.22%)
     
  • S&P 500

    4,076.57
    -3.54 (-0.09%)
     
  • DOW

    34,395.01
    -194.76 (-0.56%)
     
  • CRUDE OIL

    81.25
    +0.03 (+0.04%)
     
  • GOLD FUTURES

    1,793.90
    -21.30 (-1.17%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,557.45
    +67.15 (+0.46%)
     
  • CAC 40

    6,706.09
    -47.88 (-0.71%)
     

Medacta Group SA announces the final settlement in the Conformis case

Medacta Group SA / Key word(s): Legal Matter

15-Nov-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Press Release – Ad-hoc announcement pursuant to Art. 53 LR       

Medacta Group SA announces the final settlement in the Conformis case

CASTEL SAN PIETRO, 15 November 2022 – With reference to note 6.25 of its 2021 Financial Statements, Medacta Group SA (“Medacta”, SIX:MOVE) announces today that its subsidiaries Medacta International SA, Medacta USA, Inc. and Medacta Germany GmbH (together, “Medacta”)  have entered into an agreement with Conformis, Inc. that resolves all patent disputes between the companies.

The settlement agreement contemplates the payment of a sum in a low single digit million-dollar amount and accordingly, all matters referred to as 'the Conformis Matter' in note 6.25 of the 2021 Financial Statements are fully, finally and completely settled.

 

Contact
Medacta International SA
Corrado Farsetta, Group CFO
Phone: +41 91 696 60 60

investor.relations@medacta.ch

 

About Medacta

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

 


End of Inside Information

Language:

English

Company:

Medacta Group SA

Strada Regina

6874 Castel San Pietro

Switzerland

Phone:

+41 91 696 6060

E-mail:

info@medacta.ch

Internet:

www.medacta.com

ISIN:

CH0468525222

Listed:

SIX Swiss Exchange

EQS News ID:

1486221


 

End of Announcement

EQS News Service

show this
show this